Accueil › Lymphome de Burkitt › Géorgie › Atlanta
Essais cliniques pour Lymphome de Burkitt à Atlanta, GA
12 études pour Lymphome de Burkitt recherchent des participants dans et autour de Atlanta (dans un rayon d'environ 30 miles). Ouvrez une étude pour voir qui peut participer et comment contacter l'équipe.
Texte officiel de l'étude (anglais)
Vous recrutez pour une étude ? Mettez-la en avant en haut de cette page — $99 pour 30 jours →
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Recrutement en coursPhase 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Recrutement en coursPhase 3
- Emory University Hospital/Winship Cancer Institute, Atlanta
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recrutement en coursÉtude observationnelle
- Children's Healthcare of Atlanta - Arthur M. Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Recrutement en coursPhase 2
- Emory University Hospital/Winship Cancer Institute, Atlanta
- Emory Saint Joseph's Hospital, Atlanta
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Recrutement en coursPhase 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Recrutement en coursPhase 1
- Winship Cancer Institute Emory University, Atlanta
- Northside Hospital Cancer Institute, Atlanta
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Recrutement en coursPhase 2
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Recrutement en coursPhase 3
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Recrutement en coursPhase 1/2
- Research Site, Atlanta
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
Recrutement en coursPhase 2
- Children's Healthcare of Atlanta at Egleston, Atlanta
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
Recrutement en coursPhase 1
- Winship Cancer Institute, Emory University, Atlanta
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Recrutement en coursPhase 2
- Children's Healthcare of Atlanta, Atlanta
Essais pour Lymphome de Burkitt dans d'autres villes
- Houston, TX21 études
- Philadelphia, PA16 études
- Milwaukee, WI16 études
- Chicago, IL15 études
- Cincinnati, OH13 études
- New York City, NY13 études
- Aurora, CO11 études
- Seattle, WA11 études
- Durham, NC10 études
- Boston, MA10 études
- Kansas City, MO10 études
- Los Angeles, CA10 études
Autres études à Atlanta
- Cancer (tous types)49 études
- Cancer du poumon non à petites cellules47 études
- Myélome multiple42 études
- Cancer du sein41 études
- Cancer de la prostate33 études
- Leucémie aiguë myéloïde31 études
- Cancer de l'ovaire29 études
- Cancer colorectal29 études
- Cancer du poumon29 études
- Cancer métastatique28 études
- Trouble dépressif majeur25 études
- Insuffisance cardiaque25 études
Source : ClinicalTrials.gov, données récupérées le 6 oct. 2026. Chaque étude définit ses propres critères d'éligibilité ; l'équipe de l'étude décide qui peut y participer.